Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis - 09/08/11
Doi : 10.1016/j.jaad.2005.10.056
Douglas W. Kress, MD ⁎ 
Children’s Hospital of Pittsburgh, Wexford, Pennsylvania, University of Pittsburgh, Pittsburgh, Pennsylvania
Correspondence to: Douglas W. Kress, MD, Children’s Hospital of Pittsburgh, Pediatric Dermatology, Pine Center, Ste 108, 11279 Perry Highway, Wexford, PA 15090Plan
| This case series was investigator initiated. Financial support for the manuscript was provided by Amgen Inc and by Wyeth Research. The author wishes to thank Julia R. Gage for assistance in manuscript preparation. Conflicts of interest: Dr Kress has received an honorarium for this case series. He is on the speaker’s bureau and is a consultant for Amgen. He has not received research funds from Amgen and does not own Amgen stock. Reprints not available from the author. |
© 2006
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 54 - N° 3S2
P. S126-S128 - mars 2006 Retour au numéro
Article précédent
- Treatment of recurrent Sweet’s syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept
- Paul S. Yamauchi, Logan Turner, Nicholas J. Lowe, Vivian Gindi, J. Mark Jackson
- The treatment of pyoderma gangrenosum using etanercept
- David B. Roy, Eugene T. Conte, David J. Cohen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?